In the long human struggle against blood cancers, science has found a new ally in iNKT cells — immune sentinels that bridge the body's instinctive and learned defenses. Researchers publishing in Nature have shown that by carefully engineering these cells with optimized CAR structures, and pairing them with a purpose-built molecular engager, it becomes possible to attack multiple myeloma from two directions at once — closing the escape routes that have long allowed this cancer to outlast treatment. The work is a reminder that resilience in medicine, as in life, often comes not from a single pow
Optimized iNKT cell therapy shows promise against multiple myeloma
Dual-target therapy closed off the tumor's primary escape route
Mark
Why iNKT cells specifically? What makes them different from the CAR-T cells doctors are already using?
Mimi
iNKT cells are hybrid cells—they have both innate and adaptive immune properties. That means they wake up faster, like an instinctive response, but they're also precise, like a learned one. CAR-T cells are powerful, but they're slower to mobilize. iNKT cells can respond almost immediately while still being trainable to recognize specific targets.
Mark
And the CD28z design—why did that one win out of the five tested?
Mimi
It's about how the cell communicates with the tumor. The researchers found that CD28z CAR-iNKT cells have this crosstalk happening through two proteins—one on the immune cell, one on the myeloma cell—that amplifies the binding and killing. It's like having a conversation between the two cells that makes the immune cell grip harder and work more effectively.
Mark
But you also designed an engager molecule. Why not just use the CAR cells alone?
Mimi
Because some patients might not tolerate genetic modification, or the manufacturing might be too complex or expensive. The engager is simpler—it's a small molecule that bridges the iNKT cell to the tumor without rewriting the cell's DNA. It's a different tool for the same job.
Mark
And the dual-target approach—that's the real breakthrough?
Mimi
That's where the escape problem gets solved. Myeloma cells are clever. If you only target one protein, they'll just stop making it and hide. By hitting two targets at once, through two different mechanisms, you give the tumor nowhere to run. It's harder to evolve resistance when you're under attack from two directions simultaneously.
Mark
What happens next?
Mimi
Clinical trials. Everything we've shown works in the lab and in models. Now we need to see if it actually helps patients, and whether the side effects are manageable. That's the real test.
El Pulso
- Multiple myeloma has long frustrated immunotherapy by evolving resistance — shedding the very proteins that immune cells are trained to recognize.
- Among five engineered CAR designs tested on iNKT cells, the CD28z configuration emerged as decisively superior, driven by a newly discovered molecular conversation between Plexin D1 and Semaphorin 4A that sharpens the cell's killing power.
- A separately engineered bispecific engager molecule — designed to recruit iNKT cells against the myeloma protein BCMA — proved effective even without genetically modifying the immune cells themselves, opening a second therapeutic lane.
- When both strategies were combined into a dual-target, dual-modality approach, the therapy outperformed either method alone and blocked the tumor's primary escape mechanism — the shedding of the FCRL5 surface protein.
- The findings now move toward the harder test of clinical trials, where laboratory promise must prove itself in living patients.
In the long human struggle against blood cancers, science has found a new ally in iNKT cells — immune sentinels that bridge the body's instinctive and learned defenses. Researchers publishing in Nature have shown that by carefully engineering these cells with optimized CAR structures, and pairing them with a purpose-built molecular engager, it becomes possible to attack multiple myeloma from two directions at once — closing the escape routes that have long allowed this cancer to outlast treatment. The work is a reminder that resilience in medicine, as in life, often comes not from a single powerful blow, but from the wisdom to anticipate retreat.
Scientists have taken a significant step forward in the fight against multiple myeloma by engineering iNKT cells — a rare class of immune cells that respond with the speed of innate immunity and the precision of adaptive immunity — into more effective cancer killers than anything currently available in cell-based therapy.
The team evaluated five different CAR designs grafted onto iNKT cells to direct them against myeloma. One configuration, CD28z, outperformed all others. The reason, the researchers found, lies in a molecular dialogue between two proteins — Plexin D1 on the engineered cells and Semaphorin 4A on the tumor — that amplifies the cell's ability to bind and destroy its target. These optimized iNKT cells even surpassed CAR-T cells, the current benchmark in cellular immunotherapy.
Seeking to broaden the therapeutic toolkit, the team also designed a bispecific engager molecule tailored to iNKT cells and aimed at BCMA, a protein displayed on myeloma cells. Paired with laboratory-grown iNKT cells infused into patients, this engager demonstrated meaningful anti-tumor activity without requiring any genetic modification — a strategically simpler complement to the CAR approach.
The most consequential finding came when both strategies were deployed together. FCRL5 CAR-iNKT cells combined with the BCMA engager outperformed either treatment alone and, crucially, prevented the tumor from escaping by discarding its FCRL5 surface marker — a common evasion tactic. Attacking two targets through two distinct mechanisms simultaneously closed off that exit.
Backed by Blood Cancer UK, Cancer Research UK, and the Medical Research Council, the research points toward clinical trials as the next horizon — where the true measure of this engineering will be taken in the lives of patients.
Researchers have engineered a new approach to fighting multiple myeloma—a cancer of blood-forming cells—by optimizing immune cells called iNKT cells to hunt down and destroy tumor tissue more effectively than existing therapies. The work, published in Nature, represents a significant step forward in understanding how to weaponize these cells, which occupy a unique middle ground between the body's innate and adaptive immune systems, responding faster than conventional T cells while retaining their precision.
The team tested five different designs for CAR (chimeric antigen receptor) structures grafted onto iNKT cells, essentially engineering them to recognize and attack myeloma cells. Among the variants, one stood out: the CD28z CAR-iNKT configuration. This design worked better than the others, driven by a mechanism the researchers identified involving two proteins—Plexin D1 on the engineered immune cells and Semaphorin 4A on the myeloma cells—that appear to communicate with each other, amplifying the cell's ability to bind to and kill its target. Remarkably, these optimized iNKT cells outperformed their CAR-T counterparts, the current gold standard in cell-based cancer immunotherapy.
But the researchers did not stop there. To expand the therapeutic arsenal, they designed a second tool: a bispecific engager molecule engineered specifically to work with iNKT cells and target BCMA, a protein found on myeloma cells. When this engager was paired with adoptively transferred iNKT cells—cells grown in the laboratory and infused back into patients—it demonstrated substantial anti-myeloma activity on its own, offering a complementary strategy that does not require genetic modification of the cells themselves.
The real innovation emerged when the team combined both approaches. They used FCRL5 CAR-iNKT cells alongside the BCMA engager in a dual-target, dual-modality strategy. This combination outperformed either approach alone and, critically, prevented the tumor from escaping by shedding the FCRL5 protein—a common resistance mechanism where cancer cells simply stop displaying the target the immune system has learned to recognize. By attacking two different proteins simultaneously through two different mechanisms, the therapy closed off one of the myeloma cell's primary escape routes.
The work was supported by multiple funding bodies including Blood Cancer UK, Cancer Research UK, and the Medical Research Council, with contributions from the North West London Myeloma Support Group. The findings suggest that optimized iNKT-based immunotherapy, particularly when deployed as a dual-target system, holds promise not only for multiple myeloma but potentially for other malignancies as well. The next phase will be translating these laboratory results into clinical trials, where the real test of whether this engineering translates to benefit for patients will begin.
Citas Notables
Optimised iNKT-based, dual-target, dual-modality immunotherapy has enhanced anti-tumor activity against multiple myeloma and potentially other malignancies— Research team, Nature publication
Quieres la nota completa?
Lee el original en Nature ↗
Health & Medicine